AdAlta Ltd 1AD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.03
- Day Range
- A$0.03–0.03
- 52-Week Range
- A$0.02–0.05
- Bid/Ask
- A$0.03 / A$0.03
- Market Cap
- A$15.25 Mil
- Volume/Avg
- 344,254 / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 12
- Website
- https://www.adalta.com.au
Valuation
|
Metric
|
1AD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
1AD
|
|---|---|
Quick Ratio | 1.77 |
Current Ratio | 1.83 |
Interest Coverage | −33.76 |
Quick Ratio
1AD
Profitability
|
Metric
|
1AD
|
|---|---|
Return on Assets (Normalized) | −71.17% |
Return on Equity (Normalized) | −209.27% |
Return on Invested Capital (Normalized) | −84.92% |
Return on Assets
1AD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wmqktzcg | Lzny | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pytfvxbx | Zltydmz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fmyjrzmn | Szmgfs | $99.5 Bil | |
MRNA
| Moderna Inc | Tmlrsjt | Xqmg | $38.8 Bil | |
ARGX
| argenx SE ADR | Xkxdrjtl | Kpjj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gbqkjfjy | Gfk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ntlfhfr | Jzlqjg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kkfcdzgvm | Dsrrh | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dvcxsyzglk | Jdcrkyp | $12.5 Bil | |
INCY
| Incyte Corp | Bjkntlrz | Tqzdp | $11.6 Bil |